BridgeMD
CACH RECEVA: Calcium Channel blocker in treatment of reversible cerebral vasoconstriction syndrome: a double-blind, randomized, placebo-controlled trial.
EU CTIS ID: 2023-504547-14-01
What this study is testing
The main objective of the study is to test the hypothesis that the addition of a calcium channel blocker on top of standard care can reduce the frequency of recurrent headache attacks in patients diagnosed with reversible cerebral vasoconstriction syndrome without parenchymal lesions or subarachnoid hemorrhage on CT/MRI.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥ 18 years at entry
- Thunderclap headache (reaching peak intensity within ≤1 minute) or severe recurrent headache
- Cerebral vasoconstriction on imaging in at least 2 different arteries or cerebral vasoconstriction in one artery and typical clinical picture with thunderclap headache
- Absence of acute or subacute infarction, hemorrhage or findings suggesting posterior reversible encephalopathy syndrome on CT/MRI.
- Absence of aneurysmal subarachnoid hemorrhage (SAH)
You likely can't join if
- Ongoing usage of calcium channel blockers before the index event
- Parenchymal lesions on CT/MRI (ischemic lesions, intracerebral hemorrhage, posterior reversible encephalopathy syndrome)
- Subarachnoid hemorrhage on CT/MRI
- Clinical suspicion of PACNS or other CNS vasculitis
- An abnormal cerebrospinal fluid (CSF) finding, if a lumbar puncture is performed.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.